MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

UroGen Pharma Ltd

Slēgts

9.6 -1.44

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.2

Max

10.04

Galvenie mērījumi

By Trading Economics

Ienākumi

-14M

-38M

Pārdošana

-639K

25M

EPS

-0.8

Peļņas marža

-152.705

Darbinieki

235

EBITDA

-16M

-31M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+248.6% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 12. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

70M

489M

Iepriekšējā atvēršanas cena

11.04

Iepriekšējā slēgšanas cena

9.6

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

UroGen Pharma Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. apr. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

2025. g. 21. apr. 22:37 UTC

Iegādes, apvienošanās, pārņemšana

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

2025. g. 21. apr. 23:58 UTC

Tirgus saruna

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

2025. g. 21. apr. 23:46 UTC

Tirgus saruna

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

2025. g. 21. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

2025. g. 21. apr. 23:23 UTC

Iegādes, apvienošanās, pārņemšana

Nomura Expects Transaction to Close by End 2025

2025. g. 21. apr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

2025. g. 21. apr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

2025. g. 21. apr. 22:35 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- 2nd Update

2025. g. 21. apr. 22:02 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- Update

2025. g. 21. apr. 21:46 UTC

Top Ziņas

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

2025. g. 21. apr. 21:03 UTC

Top Ziņas

3M Earnings Will Be Scoured for Tariff Impacts -- Barrons.com

2025. g. 21. apr. 21:03 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- WSJ

2025. g. 21. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 21. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. apr. 20:43 UTC

Top Ziņas

GE Aerospace Investors Are Hoping for Reassurance, and Strong Earnings -- Barrons.com

2025. g. 21. apr. 20:28 UTC

Top Ziņas

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

2025. g. 21. apr. 20:26 UTC

Top Ziņas

Lockheed Martin's Earnings Are Coming as Investors Watch the Pentagon -- Barrons.com

2025. g. 21. apr. 20:24 UTC

Top Ziņas

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

2025. g. 21. apr. 20:18 UTC

Top Ziņas

Boeing 737 MAX Jets in China Head Home. Can They Be Resold? -- Barrons.com

2025. g. 21. apr. 19:14 UTC

Tirgus saruna

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

2025. g. 21. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

2025. g. 21. apr. 19:07 UTC

Top Ziņas

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

2025. g. 21. apr. 18:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. apr. 18:44 UTC

Tirgus saruna

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

2025. g. 21. apr. 18:28 UTC

Tirgus saruna

Gold Finishes at New Record as Equities Slide -- Market Talk

2025. g. 21. apr. 18:26 UTC

Top Ziņas

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

2025. g. 21. apr. 16:27 UTC

Tirgus saruna

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

2025. g. 21. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

UroGen Pharma Ltd Prognoze

Cenas mērķis

By TipRanks

248.6% augšup

Prognoze 12 mēnešiem

Vidējais 33.71 USD  248.6%

Augstākais 55 USD

Zemākais 16 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi UroGen Pharma Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

6

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

9.61 / 10.74Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Neutral Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.